AU2019263026B2 - Combinations for treating cancer - Google Patents

Combinations for treating cancer Download PDF

Info

Publication number
AU2019263026B2
AU2019263026B2 AU2019263026A AU2019263026A AU2019263026B2 AU 2019263026 B2 AU2019263026 B2 AU 2019263026B2 AU 2019263026 A AU2019263026 A AU 2019263026A AU 2019263026 A AU2019263026 A AU 2019263026A AU 2019263026 B2 AU2019263026 B2 AU 2019263026B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
azd5991
acalabrutinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019263026A
Other languages
English (en)
Other versions
AU2019263026A1 (en
Inventor
Scott BOIKO
Justin CIDADO
Lisa Drew
Theresa PROIA
Maryann SAN MARTIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2019263026A1 publication Critical patent/AU2019263026A1/en
Application granted granted Critical
Publication of AU2019263026B2 publication Critical patent/AU2019263026B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019263026A 2018-04-30 2019-04-29 Combinations for treating cancer Ceased AU2019263026B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862664356P 2018-04-30 2018-04-30
US62/664,356 2018-04-30
PCT/IB2019/053491 WO2019211721A1 (en) 2018-04-30 2019-04-29 Combinations for treating cancer

Publications (2)

Publication Number Publication Date
AU2019263026A1 AU2019263026A1 (en) 2020-12-17
AU2019263026B2 true AU2019263026B2 (en) 2022-06-30

Family

ID=66794041

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019263026A Ceased AU2019263026B2 (en) 2018-04-30 2019-04-29 Combinations for treating cancer

Country Status (14)

Country Link
US (1) US20210030718A1 (https=)
EP (1) EP3787620A1 (https=)
JP (1) JP2021522246A (https=)
KR (1) KR20210005182A (https=)
CN (1) CN112040944A (https=)
AU (1) AU2019263026B2 (https=)
BR (1) BR112020022020A2 (https=)
CA (1) CA3097486A1 (https=)
EA (1) EA202092540A1 (https=)
MA (1) MA52499A (https=)
MX (1) MX2020011453A (https=)
SG (1) SG11202010528XA (https=)
TW (1) TW202014184A (https=)
WO (1) WO2019211721A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158321A1 (en) * 2019-11-04 2021-05-14 Astrazeneca Ab Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
JP2023510135A (ja) * 2019-12-18 2023-03-13 ゼノ マネジメント，インコーポレイテッド 大環状化合物
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017182625A1 (en) * 2016-04-22 2017-10-26 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
CA2956550A1 (en) * 2014-08-08 2016-02-11 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017182625A1 (en) * 2016-04-22 2017-10-26 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer

Also Published As

Publication number Publication date
US20210030718A1 (en) 2021-02-04
EP3787620A1 (en) 2021-03-10
CN112040944A (zh) 2020-12-04
CA3097486A1 (en) 2019-11-07
JP2021522246A (ja) 2021-08-30
EA202092540A1 (ru) 2021-03-17
WO2019211721A1 (en) 2019-11-07
MX2020011453A (es) 2020-12-07
BR112020022020A2 (pt) 2021-02-02
MA52499A (fr) 2021-04-14
SG11202010528XA (en) 2020-11-27
KR20210005182A (ko) 2021-01-13
TW202014184A (zh) 2020-04-16
AU2019263026A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
JP7114478B2 (ja) 癌の治療のための配合剤
AU2019263026B2 (en) Combinations for treating cancer
KR20240167633A (ko) 종양 치료용 약학 조성물
CN113382731A (zh) 包含tno155和瑞博西尼的药物组合
CN105050623B (zh) Pi3k抑制剂和c-met抑制剂的组合
CA2730190A1 (en) Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
JP2019511526A (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
CN105338980A (zh) 药物组合
CN116847874A (zh) Dhodh抑制剂化合物在组合癌症疗法中的用途
WO2021210636A1 (ja) 乳がん治療剤
JP2025529199A (ja) がんの治療で使用するためのｄｃｃ－３１１６とｍａｐｋａｐ経路阻害剤との併用
EP3999065B1 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
HK40041700A (en) Combinations for treating cancer
KR20240055021A (ko) Tead 저해제에 대한 투여 요법
CN102105148B (zh) 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
HK40127185A (zh) 雌激素受体降解剂的给药方案
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib
US20100022553A1 (en) Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
CA2638270A1 (en) Therapeutic combination comprising an aurora kinase inhibitor and imatinib

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired